{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:59:47Z","timestamp":1777417187132,"version":"3.51.4"},"reference-count":20,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2000,9,1]],"date-time":"2000-09-01T00:00:00Z","timestamp":967766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2000,9]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To compare the dosing requirements and international normalized ratios (INRs) associated with two bioequivalent crystalline warfarin sodium products in patients with chronic atrial fibrillation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>A multicenter, single-blind (prescriber), randomized, crossover evaluation of Apothecon warfarin and DuPont warfarin (Coumadin) was conducted in consenting adults with chronic or paroxysmal atrial fibrillation who had been receiving DuPont warfarin chronically for the prevention of thromboembolism. Patients were randomly assigned to initially either continue DuPont warfarin or receive Apothecon warfarin for four weeks, with weekly evaluation of dosage and INR changes, safety, and efficacy. Subsequently, patients crossed over and received the other product for four weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>There were 113 patients randomized to receive study treatment. Neither the propensity for a dosage change or an INR change nor the magnitude of a dosage change or INR change appeared related to a particular warfarin product (NS for each variable after each study period). After four weeks of treatment, the same number of patients (n = 7) experienced a \u226520% change in warfarin dosage from the respective baseline with each product. The number of patients with INRs outside the desired protocol range after four weeks of treatment was similar for both groups (&lt;1.8, n = 9 for both products, or &gt;3.2, n = 9 for DuPont, n = 10 for Apothecon). No major hemorrhagic or thromboembolic events occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>The results of this study show that Apothecon warfarin and DuPont warfarin provide equivalent anticoagulation in patients with chronic or paroxysmal atrial fibrillation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.10068","type":"journal-article","created":{"date-parts":[[2003,6,3]],"date-time":"2003-06-03T16:38:27Z","timestamp":1054658307000},"page":"981-988","source":"Crossref","is-referenced-by-count":18,"title":["A Randomized, Crossover Comparison of Warfarin Products in the Treatment of Chronic Atrial Fibrillation"],"prefix":"10.1177","volume":"34","author":[{"given":"Robert T","family":"Weibert","sequence":"first","affiliation":[{"name":"Robert T Weibert PharmD, Clinical Professor, Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, San Francisco, CA; Associate Clinical Professor, Department of Family and Preventive Medicine, School of Medicine, University of California, San Diego, San Diego, CA; Anticoagulation Clinical Director, University of California, San Diego Medical Center, San Diego, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan F","family":"Yeager","sequence":"additional","affiliation":[{"name":"Bryan F Yeager PharmD BCPS, Assistant Professor, Colleges of Pharmacy and Medicine, University of Kentucky, Lexington, KY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann K","family":"Wittkowsky","sequence":"additional","affiliation":[{"name":"Ann K Wittkowsky PharmD CACP, Director, Anticoagulation Services, Clinical Pharmacist, Cardiology, Clinical Associate Professor, University of Washington Medical Center, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry I","family":"Bussey","sequence":"additional","affiliation":[{"name":"Henry I Bussey PharmD FCCP, Professor, College of Pharmacy, The University of Texas at Austin, Austin, TX, and the University of Texas Health Science Center at San Antonio, San Antonio, TX; Clinical Director, Anticoagulation Clinics of North America, San Antonio, TX; Co-founder, , Austin, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B","family":"Wilson","sequence":"additional","affiliation":[{"name":"David B Wilson MD, Associate Professor, Section of Cardiovascular Diseases, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E","family":"Godwin","sequence":"additional","affiliation":[{"name":"John E Godwin MD MS, Associate Professor of Medicine and Pathology, Loyola University Chicago, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S","family":"Adler","sequence":"additional","affiliation":[{"name":"David S Adler PharmD, Professor of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco; San Diego Program, University of California, San Diego Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A","family":"Black","sequence":"additional","affiliation":[{"name":"Elizabeth A Black BA, Clinical Research Associate, Clinical Research & Investigator Services, University HealthSystem Consortium, Oak Brook, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel L","family":"McGee","sequence":"additional","affiliation":[{"name":"Daniel L McGee PhD, at time of writing, Professor and Head, Section of Biostatistics, Preventative Medicine and Epidemiology, Loyola University Medical Center, Chicago, IL; now, Professor, Department of Biometry and Epidemiology, Medical University of South Carolina, Charleston, SC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter H","family":"Vlasses","sequence":"additional","affiliation":[{"name":"Peter H Vlasses PharmD BCPS FCCP, at time of writing, Director, Clinical Research and Investigator Services, University HealthSystem Consortium, Oak Brook, IL; now, Executive Director, The American Council on Pharmaceutical Education, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2000,9,1]]},"reference":[{"key":"bibr1-aph.10068","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.19.1830"},{"key":"bibr2-aph.10068","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90285-W"},{"key":"bibr3-aph.10068","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199608223350802"},{"key":"bibr4-aph.10068","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199507063330103"},{"key":"bibr5-aph.10068","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(96)00020-4"},{"key":"bibr6-aph.10068","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1995.tb04379.x"},{"key":"bibr7-aph.10068","first-page":"187","volume-title":"Applied clinical pharmacokinetics","author":"Sawyer W","year":"1983"},{"key":"bibr8-aph.10068","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/55.7.727"},{"key":"bibr9-aph.10068","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/55.7.729"},{"key":"bibr10-aph.10068","doi-asserted-by":"publisher","DOI":"10.1378\/chest.113.2.261"},{"key":"bibr11-aph.10068","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1997.tb03741.x"},{"key":"bibr12-aph.10068","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1988.00380040046010"},{"key":"bibr13-aph.10068","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/55.7.686"},{"key":"bibr14-aph.10068","first-page":"47","volume":"41","author":"Generic drugs","year":"1999","journal-title":"Medical Lett"},{"key":"bibr15-aph.10068","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/57.5.452"},{"key":"bibr16-aph.10068","first-page":"49","volume":"19","author":"Neutal JM","year":"1998","journal-title":"Cardiovasc Rev Rep"},{"key":"bibr17-aph.10068","first-page":"13","volume":"4","author":"Handler J","year":"1998","journal-title":"Prev Cardiol"},{"key":"bibr18-aph.10068","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1998.tb03919.x"},{"key":"bibr19-aph.10068","doi-asserted-by":"publisher","DOI":"10.1592\/phco.20.3.240.34784"},{"key":"bibr20-aph.10068","first-page":"5","volume-title":"Principles of pharmacoeconomics","author":"Bootman JL","year":"1996","edition":"2"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.10068","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.10068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:03:39Z","timestamp":1777374219000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.10068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,9]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2000,9]]}},"alternative-id":["10.1345\/aph.10068"],"URL":"https:\/\/doi.org\/10.1345\/aph.10068","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,9]]}}}